Immunocore Holdings (IMCR) Non Operating Income (2021 - 2023)
Immunocore Holdings (IMCR) posted Non Operating Income of $2.3 million for Q2 2023, up 363.44% sequentially from -$877350.4 in Q4 2022, and up 238.73% YoY from $682342.4 in Q2 2022.
Immunocore Holdings (IMCR) Non Operating Income (2021 - 2023) Analysis & Trends
Immunocore Holdings has reported Non Operating Income for 3 years, with the latest figure at $2.3 million in Q2 2023.
- Quarterly Non Operating Income rose 238.73% year-over-year to $2.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$1.6 million (changed N/A YoY) and the FY2022 annual result came in at -$5.3 million, up 32.91% from the prior year.
- Non Operating Income climbed to $2.3 million in Q2 2023 per IMCR's latest filing, from -$877350.4 in the prior quarter.
- Over five years, Non Operating Income peaked at $2.3 million in Q2 2023 and troughed at -$1.8 million in Q4 2021.
- A 3-year average of -$874535.8 and a median of -$1.5 million in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income rose 22.41% in 2022, then surged 238.73% in 2023.
- Over 3 years, Non Operating Income stood at -$1.8 million in 2021, then jumped by 51.54% to -$877350.4 in 2022, then jumped by 363.44% to $2.3 million in 2023.
- According to Business Quant data, Non Operating Income over the past three periods registered $2.3 million, -$877350.4, and -$1.4 million for Q2 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immunocore Holdings | 1.76 Bn | 880.92 Mn | 114.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2.31 Mn |
| Dec 31, 2022 | -877,350.38 |
| Sep 30, 2022 | -1.40 Mn |
| Jun 30, 2022 | -1.67 Mn |
| Dec 31, 2021 | -1.81 Mn |
| Sep 30, 2021 | -1.80 Mn |